Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
CNOOC
00883
5
SINOPEC CORP
00386
| (FY)Dec 31, 2025 | (Q6)Jun 30, 2025 | (FY)Dec 31, 2024 | (Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (FY)Dec 31, 2021 | (Q6)Jun 30, 2021 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash flow from operating activities | ||||||||||
| Earning before tax | -0.73%6.94B | ---- | 17.88%6.99B | ---- | 2.68%5.93B | ---- | -68.89%5.78B | ---- | 270.49%18.57B | ---- |
| Profit adjustment | ||||||||||
| Interest (income) - adjustment | -26.77%-633.59M | ---- | -29.99%-499.78M | ---- | -90.86%-384.47M | ---- | -24.30%-201.44M | ---- | 16.47%-162.06M | ---- |
| Dividend (income)- adjustment | -101.58%-1.52B | ---- | -764.98%-753.43M | ---- | -513.71%-87.1M | ---- | -495.59%-14.19M | ---- | 47.42%-2.38M | ---- |
| Investment loss (gain) | -126.73%-219.64M | ---- | 35.80%-96.87M | ---- | 49.56%-150.9M | ---- | 24.35%-299.15M | ---- | -22.91%-395.45M | ---- |
| Attributable subsidiary (profit) loss | 27.96%151.38M | ---- | -77.50%118.3M | ---- | 243.65%525.71M | ---- | 101.12%152.98M | ---- | -421,714.29%-13.63B | ---- |
| Impairment and provisions: | -41.75%426.28M | ---- | 6,069.18%731.82M | ---- | -152.56%-12.26M | ---- | -96.71%23.33M | ---- | 787.28%708.38M | ---- |
| -Impairment of property, plant and equipment (reversal) | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -72.51%3.75M | ---- |
| -Impairment of trade receivables (reversal) | 26.62%16.19M | ---- | 204.29%12.79M | ---- | -412.28%-12.26M | ---- | 142.20%3.93M | ---- | --1.62M | ---- |
| -Impairment of goodwill | ---- | ---- | --18.62M | ---- | ---- | ---- | ---- | ---- | --47.25M | ---- |
| -Other impairments and provisions | -41.45%410.09M | ---- | --700.42M | ---- | ---- | ---- | -97.04%19.4M | ---- | 890.55%655.75M | ---- |
| Revaluation surplus: | 136.55%1.53B | ---- | 3,836.83%645.76M | ---- | -94.22%16.4M | ---- | 681.04%283.71M | ---- | 106.84%36.33M | ---- |
| -Derivative financial instruments fair value (increase) | ---- | ---- | ---- | ---- | 37.72%-47.15M | ---- | 68.60%-75.7M | ---- | -173.92%-241.07M | ---- |
| -Other fair value changes | 136.55%1.53B | ---- | 916.16%645.76M | ---- | -82.32%63.55M | ---- | 29.57%359.41M | ---- | 162.56%277.4M | ---- |
| Asset sale loss (gain): | 99.10%-11.17M | ---- | -323.33%-1.25B | ---- | -8,401.27%-294.57M | ---- | -181.00%-3.47M | ---- | 621.42%4.28M | ---- |
| -Loss (gain) from sale of subsidiary company | 99.94%-729K | ---- | -420.14%-1.21B | ---- | ---231.88M | ---- | ---- | ---- | ---- | ---- |
| -Loss (gain) on sale of property, machinery and equipment | 74.47%-10.44M | ---- | 34.76%-40.9M | ---- | -1,709.21%-62.69M | ---- | -181.00%-3.47M | ---- | 621.42%4.28M | ---- |
| Depreciation and amortization: | -8.30%1.21B | ---- | 22.98%1.32B | ---- | 2.61%1.07B | ---- | 5.48%1.05B | ---- | -40.02%992.56M | ---- |
| -Amortization of intangible assets | 7.58%187.84M | ---- | 60.04%174.6M | ---- | 7.29%109.1M | ---- | 13.09%101.69M | ---- | -88.22%89.92M | ---- |
| Financial expense | -5.69%278.31M | ---- | -42.25%295.12M | ---- | 16.40%511.07M | ---- | 42.27%439.06M | ---- | -4.56%308.62M | ---- |
| Special items | 1,693.72%115.96M | ---- | -94.18%6.47M | ---- | -24.14%111.08M | ---- | --146.42M | ---- | ---- | ---- |
| Operating profit before the change of operating capital | 10.05%8.27B | ---- | 3.77%7.52B | ---- | -1.50%7.24B | ---- | 14.31%7.35B | ---- | 6.79%6.43B | ---- |
| Change of operating capital | ||||||||||
| Inventory (increase) decrease | 142.66%116.48M | ---- | -301.79%-273.06M | ---- | 134.60%135.32M | ---- | -580.47%-391.1M | ---- | 74.05%-57.48M | ---- |
| Accounts receivable (increase)decrease | 202.57%534.4M | ---- | 18.52%-520.99M | ---- | -36.03%-639.41M | ---- | 70.90%-470.06M | ---- | -975.26%-1.62B | ---- |
| Accounts payable increase (decrease) | 154.97%2B | ---- | 12.45%783.39M | ---- | -37.28%696.68M | ---- | 29.49%1.11B | ---- | 19.61%857.86M | ---- |
| prepayments (increase)decrease | -208.03%-87.76M | ---- | 116.90%81.24M | ---- | 7.52%-480.79M | ---- | -226.96%-519.9M | ---- | 293.39%409.49M | ---- |
| Special items for working capital changes | 118.55%63.95M | ---- | 120.56%29.26M | ---- | -290.73%-142.32M | ---- | 12.64%74.62M | ---- | -48.06%66.25M | ---- |
| Cash from business operations | 43.07%10.9B | ---- | 11.79%7.62B | ---- | -4.82%6.81B | ---- | 17.47%7.16B | ---- | -3.05%6.09B | ---- |
| Other taxs | -60.29%-1.6B | ---- | -34.04%-1B | ---- | 16.31%-746.57M | ---- | -22.76%-892.09M | ---- | 24.24%-726.72M | ---- |
| Special items of business | ---- | 2.66%3.16B | ---- | 15.25%3.08B | ---- | -32.36%2.67B | ---- | 69.08%3.95B | ---- | 50.14%2.34B |
| Net cash from operations | 40.46%9.29B | 2.66%3.16B | 9.06%6.62B | 15.25%3.08B | -3.18%6.07B | -32.36%2.67B | 16.75%6.27B | 69.08%3.95B | 0.77%5.37B | 50.14%2.34B |
| Cash flow from investment activities | ||||||||||
| Interest received - investment | 26.77%633.59M | ---- | 29.99%499.78M | ---- | 90.86%384.47M | ---- | 24.30%201.44M | ---- | -16.47%162.06M | ---- |
| Dividend received - investment | 6.38%1.52B | 100.04%1.5B | 190.07%1.43B | --751.67M | -44.83%492.91M | ---- | -77.76%893.45M | ---- | 46,383.92%4.02B | ---- |
| Loan receivable (increase) decrease | ---- | ---- | ---- | ---- | ---- | ---- | 318.80%70.43M | ---- | 39.71%-32.19M | ---- |
| Decrease in deposits (increase) | 27.80%-2.34B | -27.62%-4.85B | -1,178.45%-3.24B | -38.37%-3.8B | 107.86%300.52M | -5.42%-2.74B | -62.20%-3.82B | -510.08%-2.6B | -6.87%-2.36B | --634.89M |
| Sale of fixed assets | -31.22%48.73M | ---- | -29.84%70.85M | ---- | 262.09%100.99M | ---- | -78.90%27.89M | ---- | 30.69%132.2M | ---- |
| Purchase of fixed assets | -29.02%-1.24B | 33.53%-270.85M | 10.09%-960.1M | 45.95%-407.5M | 14.12%-1.07B | -20.25%-753.91M | 27.47%-1.24B | -7.06%-626.97M | -20.35%-1.71B | ---585.61M |
| Purchase of intangible assets | -6.93%-464.16M | ---- | -6.71%-434.06M | ---- | 12.01%-406.78M | ---- | -157.04%-462.29M | ---- | 58.64%-179.85M | ---- |
| Sale of subsidiaries | -75.30%346.83M | -75.44%346.17M | 239.37%1.4B | --1.41B | 383.11%413.81M | ---- | ---146.17M | ---- | ---- | ---- |
| Acquisition of subsidiaries | -189,047.14%-5.02B | ---- | 100.23%2.66M | ---- | ---1.16B | --458K | ---- | ---- | ---798.75M | ---757.16M |
| Recovery of cash from investments | 3.67%301.54M | ---- | 71.43%290.86M | ---- | -19.35%169.67M | ---- | -2.77%210.37M | ---- | --216.37M | ---- |
| Cash on investment | -139.47%-448.81M | -3,097.60%-4.28B | 448.97%1.14B | 65.16%-133.93M | -256.67%-325.86M | 88.60%-384.45M | 96.54%-91.36M | -116.05%-3.37B | 70.80%-2.64B | ---1.56B |
| Other items in the investment business | -201.22%-5.75B | 90.82%261.93M | -665.54%-1.91B | 171.50%137.27M | 16.07%337.63M | -131.32%-191.99M | -56.83%290.87M | 134.29%612.94M | -86.52%673.81M | -16.54%-1.79B |
| Net cash from investment operations | -626.32%-12.41B | -257.13%-7.29B | -125.78%-1.71B | 49.91%-2.04B | 81.40%-756.98M | 31.97%-4.07B | -61.80%-4.07B | -47.68%-5.99B | 67.93%-2.52B | -164.48%-4.06B |
| Net cash before financing | -163.64%-3.12B | -497.87%-4.13B | -7.59%4.91B | 173.92%1.04B | 141.93%5.31B | 31.22%-1.4B | -23.01%2.19B | -18.62%-2.04B | 213.10%2.85B | -7,932.88%-1.72B |
| Cash flow from financing activities | ||||||||||
| New borrowing | 16.29%13.6B | -27.47%4.87B | -4.08%11.7B | -38.57%6.71B | 25.03%12.19B | 41.55%10.93B | 593.65%9.75B | 1,310.46%7.72B | -8.57%1.41B | --547.29M |
| Refund | 50.10%-7.2B | 72.15%-2.62B | -40.33%-14.43B | 7.91%-9.4B | -46.25%-10.28B | -55.11%-10.2B | -174.02%-7.03B | -716.55%-6.58B | -45.80%-2.57B | ---805.6M |
| Interest paid - financing | 4.64%-273.91M | ---- | 40.26%-287.25M | ---- | -41.62%-480.83M | ---- | -89.02%-339.52M | ---- | 16.57%-179.62M | ---- |
| Dividends paid - financing | 17.84%-1.82B | 97.08%-25.94M | 42.54%-2.21B | -62.85%-889.22M | -29.99%-3.85B | -494.20%-546.05M | -119.42%-2.97B | 70.83%-91.9M | 50.22%-1.35B | ---315.04M |
| Issuance expenses and redemption of securities expenses | 89.97%-125.63M | 65.25%-125.64M | 68.84%-1.25B | 90.73%-361.55M | -58.22%-4.02B | -65.88%-3.9B | -327.88%-2.54B | ---2.35B | -203.81%-593.56M | ---- |
| Other items of the financing business | -92.01%17.46M | -216.86%-522.73M | 444.04%218.54M | 48.00%-164.97M | -376.78%-63.52M | -101.50%-317.28M | -83.63%22.95M | 16.39%-157.46M | 671.36%140.16M | -103.69%-188.34M |
| Net cash from financing operations | 165.83%4.16B | 138.47%1.58B | 3.57%-6.32B | -1.42%-4.1B | -105.53%-6.55B | -176.76%-4.04B | 1.21%-3.19B | -91.75%-1.46B | -244.42%-3.23B | -114.90%-761.69M |
| Effect of rate | -12.87%118.07M | -212.71%-29.6M | 49.70%135.52M | -69.04%26.27M | 91.29%90.52M | 358.23%84.83M | 107.28%47.32M | 71.12%-32.85M | -332.03%-649.71M | -17.28%-113.77M |
| Net Cash | 173.47%1.04B | 16.68%-2.55B | -13.62%-1.41B | 43.77%-3.06B | -25.02%-1.24B | -55.54%-5.45B | -164.59%-992.05M | -41.06%-3.5B | -30.63%-374.95M | -148.36%-2.48B |
| Begining period cash | -16.97%6.23B | -16.97%6.23B | -13.28%7.51B | -13.28%7.51B | -9.84%8.65B | -9.84%8.65B | -9.64%9.6B | -9.64%9.6B | -0.07%10.62B | -0.07%10.62B |
| Cash at the end | 18.51%7.38B | -18.32%3.65B | -16.97%6.23B | 35.69%4.47B | -13.28%7.51B | -45.69%3.29B | -9.84%8.65B | -24.45%6.07B | -9.64%9.6B | -48.76%8.03B |
| Cash balance analysis | ||||||||||
| Cash and bank balance | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -24.46%4.21B | ---- | -38.23%5.58B |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS |
| Audit Opinions | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- |
| Auditor | Ernst & Young | -- | Ernst & Young | -- | Ernst & Young | -- | Ernst & Young | -- | Ernst & Young | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.